NCT00055536已完成2 期
A Phase II, Multi-Center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Efficacy of Intravenous Antegren (Natalizumab) in Crohn's Disease Subjects Concurrently Receiving Remicade (Infliximab) and Not in Remission
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Biogen
- 入组人数
- 60
- 试验地点
- 36
研究概览
简要总结
The purpose of this study is to determine the safety, tolerability, and efficacy of natalizumab in individuals diagnosed with active Crohn's Disease that are not in remission (CDAI greater than/equal to 150) and are currently taking Remicade. It is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. These cells are thought to cause damage in the bowel leading to the symptoms of Crohn's disease.
Patients who complete this study may be eligible for long-term natalizumab therapy via extension protocol ELN100226-351.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female patients at least 18 years of age with at least a six-month history of Crohn's disease and who are currently receiving Remicade and are not in remission (CDAI greater than/equal to 150)
- •Women must not be breastfeeding or pregnant, and must not become pregnant during the study.
排除标准
- 未提供
研究者
研究点 (36)
Loading locations...
相似试验
终止
2 期
Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving MethotrexateRheumatoid ArthritisNCT00083759Biogen299
已完成
3 期
Safety and Efficacy of Natalizumab in the Treatment of Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingNCT00027300Biogen900
已完成
2 期
Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic StrokeAcute Ischemic StrokeNCT02730455Biogen277
已完成
3 期
A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's DiseaseCrohn's DiseaseNCT00078611Biogen462
已完成
3 期
Safety and Efficacy of Natalizumab in the Treatment of Crohn's DiseaseCrohn's DiseaseNCT00032799Biogen905